Diagnosis and treatment of juvenile myelomonocytic leukemia in Slovak Republic: novel approaches

O. FABRI1,2,*, J. HORAKOVA1, I. BODOVA1, P. SVEC1, Z. LALUHOVA STRIEZENCOVA1, E. BUBANSKA1, M. CERMAK4, V. GALISOVA1, K. SKALICKA1, A. VASKA1, D. DOCZYOV2, A. PANIKOV2, T. SYKORA1, J. ADAMCAKOVA2, A. KOLENOVA2,*

1Hematology and Transfusiology Department, National Institute of Children's Diseases and Medical Faculty, Comenius University, Bratislava, Slovakia; 2Department of Pediatric Hematology and Oncology, National Institute of Children's Diseases and Medical Faculty, Comenius University, Bratislava, Slovakia; 3Department of Pediatric Hematology and Oncology, Children's Hospital, Banská Bystrica, Slovakia; 4Department of Medical Genetics, National Cancer Institute, Bratislava, Slovakia; 5Laboratory of Clinical and Molecular Genetics, Department of Pediatrics, National Institute of Children’s Diseases and Medical Faculty, Comenius University, Bratislava, Slovakia

*Correspondence: fabri.oksana@gmail.com; sasa.kolenova@gmail.com

Received December 31, 2018 / Accepted February 18, 2019

Juvenile myelomonocytic leukemia (JMML) is a rare, aggressive clonal myeloproliferative disorder of infancy and early childhood caused by oncogenic mutations in genes involved in the Ras pathway. Long-term survival has only been achieved with hematopoietic stem cell transplantation (HSCT), being able to cure more than 50% patients. To manage the disease before HSCT remains an important issue with constant searching for optimal treatment modalities. According to several retrospective analyses, azacitidine (AZA) induced clinical and molecular responses in patients with relapsed JMML pre-transplant and post-transplant, suggesting its use as a promising “bridging” therapy before HSCT.

In this paper we report our first consecutive cohort of patients with JMML treated at our institution as well as our experience with the diagnosis, novel treatment and management of these patients before the HSCT. We present 6 patients with JMML, harboring different somatic mutations (PTPN11 and NRAS), with distinct clinical features; 3 of them had been treated with AZA 75 mg/m² i.v. on days 1 to 7 of a 28-day cycle before the HSCT. Response to therapy was evaluated after each cycle in accordance with the International response criteria. One patient had a progression of splenomegaly during the treatment and after three cycles he was urgently transplanted. At the present, he is remaining in complete remission 3 years after HSCT. Two patients showed impressive response following the first cycle of the therapy with a regression of splenomegaly and monocyte count, normalized leukocytes, platelets and absent blasts in peripheral blood. The treatment was well tolerated with no adverse effect recorded.

The clinical activity and favorable toxicity of AZA in JMML provide a rationale for its use as a “bridging” therapy before HSCT. Prospective trials with accompanying translational studies are required to provide further information regarding individual factors that may direct the most appropriate choice of pretransplantation therapy.

Key words: juvenile myelomonocytic leukemia, hypomethylation, azacitidine, hematopoietic stem cell transplantation

Juvenile myelomonocytic leukemia (JMML) is a rare aggressive clonal disorder of infancy and early childhood with an estimated incidence of 1.2 cases per million children per year [1, 2, 3]. According to the WHO classification of tumors of hematopoietic and lymphoid tissues published in 2008, it is considered a separate bridging disorder between myelodysplastic syndrome (MDS) and myeloproliferative neoplasia and represents 2% to 3% of all pediatric hematologic malignancies [1, 4, 5]. The median age at diagnosis is two years, with a male to female ratio of 2:1 [6, 7].

The disease is characterized by excessive myelomonocytic cell proliferation and granulocyte-macrophage colony-stimulating factor (GM-CSF) hypersensitivity [8]. Clinically, patients generally present with pallor, fever, infection, bruising, lymphadenopathy, marked splenomegaly and hepatomegaly [1, 6, 9, 10, 11]. Leukocytosis with monocytosis, anemia, thrombocytopenia, elevated HbF and a low number of circulating myeloid precursor cells are common findings in the peripheral blood (PB) [1, 6, 7, 9–13]. Bone marrow (BM) is hypercellular with myeloid hyperplasia, scarce megakaryocytes and less than 20% of myeloid blasts [5]. The hallmark genetic features of JMML are somatic and/or germline mutations of Ras pathway genes causing deregulation of signaling within the RAS-RAF-MAPK (mitogen-
activated protein kinase) signaling pathway that results in its constant and pathological activation [4, 15]. Molecular aberrations in RAS-pathway have recently been included in the diagnostic criteria of the JMML [2, 5, 16]. Differential diagnosis should include diseases that could mimic JMML: human herpesvirus infections (Epstein-Barr virus (EBV), cytomegalovirus (CMV), human herpes virus (HHV), parvovirus B19, Wiskott-Aldrich syndrome, leukocyte-adhesion deficiency, infantile malignant osteopetrosis and hemophagocytic lymphohistiocytosis [17–21]. The clinical course is variable depending on the molecular mutations in RAS signaling pathway, epigenetic aberrations (aberrant DNA methylation) and cytogenetic abnormalities. Age >2 years at diagnosis, platelet count <33 × 10^9/l, and levels of HbF >10% have been reported as the main predictors of short survival [6, 22]. Progression to blast crisis is infrequent and the progression rate reported by different study groups ranges from 9.8% to 18% [23, 24].

Currently, allogeneic HSCT is the only effective treatment being able to cure more than 50% of JMML patients. In most cases, JMML is a fatal disease if left untreated. The majority of children succumb to respiratory failure as a result of pulmonary infiltration of leukemic cells 10–12 months after the diagnosis [6]. All children with JMML and NF-1, somatic PTPN11 mutations, K-RAS mutations, and the vast majority of children with somatic N-RAS mutations should be transplanted as soon as possible after establishing the diagnosis. A watch and wait strategy is advised for children with germline CBL mutations, some somatic NRAS mutations and in Noonan syndrome patients because of reported spontaneous resolution of myeloproliferation. HSCT should be considered if chromosomal aberrations occur or if disease progresses. In our paper we report our first consecutive cohort of patients with JMML who were diagnosed at our institution using molecular genetic analysis of genes of the RAS-RAF-MAPK pathway. We report here our first experience with hypomethylating treatment of JMML patients as “bridging” therapy before the HSCT.

Patients and methods

Between 2013 and 2018, six children with JMML were diagnosed and treated at the National Institute of Children's Diseases in Bratislava, Slovakia. The diagnosis was made in accordance with the criteria of the International JMML Working Group [1, 13]. Bone marrow and peripheral blood smears were reviewed by reference investigators of the European Working Group of Myelodysplastic Syndromes in Childhood (EWOG-MDS). Molecular genetic testing of PTPN11, NRAS, KRAS, and CBL genes were studied at the University of Freiburg in the EWOG-MDS center and the Laboratory of Clinical and Molecular Genetics at the National Institute of Children's Diseases (Bratislava, Slovakia). Complete remission (CR) of JMML after therapy was defined if all the following criteria were fulfilled: (i) no evidence of circulating blasts in PB, BM with less than 5% blasts and trilineage hematological recovery; (ii) absence of chromosome abnormalities and (iii) disappearance of clinical symptoms of JMML, such as organomegaly. Partial remission and progression of the disease were diagnosed in accordance with previously published criteria [25].

Results

Patients' characteristics at the diagnosis are presented in Table 1. Median age at presentation was 3.5 years (range 0.1–7.0). There was a male predominance with a male to female ratio of 2:1. Splenomegaly at the time of diagnosis was noted in all children with median size of 4.3 cm under costal margin.

Hematological data. At diagnosis, the mean white blood cell (WBC) was 45.82 × 10^9/l (range 18.24–132.0); 5 patients had WBC less than 50 × 10^9/l with only one child having hyperleukocytosis exceeding 100 × 10^9/l. Monocytosis was evident in all cases with mean absolute monocyte count 7.35 × 10^9/l. All patients had high HbF (median 25.67%; range 4.0–69.4) and low PLT (median 61.1%; range 35.0–92.0). The percentage of blasts in PB ranged from 1% to 5% and in BM from 3% to 20% (Table 1).

Chromosomal analyses of BM cells were performed by standard techniques at the national reference laboratory in all patients and confirmed a normal karyotype in 5 children. In one case (patient 3) conventional cytogenetics (G-banding) revealed composite karyotype with 47–49 chromosomes, deletion of long arm of chromosome 6 in region 6q21 (=del(6q21)) and two different marker chromosomes (structurally abnormal chromosomes that cannot be unambiguously identified) each in two copies; she had somatic PTPN11 mutation and shortly after the diagnosis developed a blast crisis. BCR-ABL fusion gene was excluded in all patients (Table 1).

Gene mutation analysis was performed in all patients using Sanger sequencing, a method based on the selective incorporation of chain-terminating dideoxynucleotides performed with ABI PRISM 3100. Three patients were diagnosed with somatic NRAS mutation, two with somatic PTPN11 and one child was diagnosed both with Noonan syndrome and germinal PTPN11 mutation (Table 2).

Treatment. Mean time from diagnosis to HSCT was 5.4 months (range 3.0–10.0). Depending on the clinical situation, time at the diagnosis and availability of a donor, children received different type of treatment to control the disease burden before the HSCT (Table 2). Two children received a combination of mercaptopurine (6MP) and cytarabine (ARA-C), one child AZA + 6MP, one child AZA + 6MP + ARA-C, and in one patient the disease was controlled with AZA single therapy. Four out of 5 patients had a partial remission before the HSCT. Five patients underwent allogeneic HSCT with myeloablative conditioning consisting of busulfan, cyclophosphamide and melphalan (BuCyMel).
Four are alive in a complete remission with median follow-up 1.6 years after HSCT (range 0.3–4.0 years); one girl with blast crisis at diagnosis died from transplant-related causes on day 56+ following HSCT. A child with Noonan syndrome and germline mutation was successfully treated with 6MP alone (Table 3).

**Discussion**

The clinical and laboratory features of the patients presented here are in accordance with previously published studies [4, 6, 7]. There was a male predominance, with a male to female rate of 2:1. Splenomegaly, lymphadenopathy,
recurrent infections, bleeding, monocytosis, low blasts percentage in peripheral blood and bone marrow smears as well as mutations in RAS genes were the hallmarks of the disease. According to current studies, approximately 90% of patients with JMML have mutually exclusive mutations in PTPN11, NF1, NRAS, KRAS and CBL in their leukemic cells [1, 11, 14, 15, 25, 26]. Altogether, 35% of patients with JMML show somatic mutations in PTPN11, while 20–25% of them aberrations in the RAS and 15% in the CBL gene, and 11% of children with JMML were diagnosed with clinical NF1 [6, 27–29]. Still, it is not clearly understood which type of Ras pathway determines treatment resistance or disease progression.

In our cohort, three children with somatic NRAS mutations showed completely different disease course requiring different treatment approach before the HSCT (Table 1). All three patients presented with PLT >33 × 10^9/L, had different levels of HbF (two of them had HbF <15%, one 29.0%) and showed NRAS mutations involving different codons with different amino acid substitutions. In patient 1, with NRAS mutation affecting codon 12 who had a favorable PLT count (55.0 × 10^9/L) and low HbF (4%), “watch and wait” strategy was applied for almost 10 months until she developed disease progression and was urgently transplanted. To control myeloproliferation we used both 6MP and low dose ARA-C. Patient 3 with somatic NRAS mutation affecting codon 13 presented at the age of 7 years with extremely aggressive disease, blast crisis and severe respiratory symptoms due to infiltration of the lungs by myelomonocytic cells. At presentation her PLT count was 63.0 × 10^9/L and her HbF was 4.95%. She required several courses of cytoreduction with 6MP with good hematological response but progression of splenomegaly and worsening her respiratory symptoms due to infiltration of the lungs by myelomonocytic cells. At presentation her PLT count was 63.0 × 10^9/L and her HbF was 4.95%. She required several courses of cytoreduction with 6MP with good hematological response but progression of splenomegaly and worsening her respiratory symptoms. She was transplanted 4 months later, successfully engrafted but died on D56+ from grade IV GVHD. In patient 5, a novel heterozygous 15bp insertion in NRAS exon 3 c.181_182insTGGATACAGATGGTA; [p.Q61LDTSK] was identified. Despite borderline platelet count (36.0 × 10^9/L) and high HbF (29.0%) at diagnosis, the disease had a relatively stable course. This patient received 3 courses of AZA before the HSCT with good tolerance and no adverse effects. He showed remarkable response straight after the first cycle with lowering WBC and regression of splenomegaly. He was successfully transplanted and has been disease free for 5 months now after HSCT.

It is not known at the time how RAS pathway mutations relate to the heterogeneous disease biology and variable clinical outcome of JMML patients. Some genotype-phenotype correlation studies reported that JMML patients with NRAS mutations have a rather favorable course, including some cases with spontaneous disease regression [30, 31]. Matsuda et al. suggested a mild clinical course for the G12S substitution in N-RAS or K-RAS protein [30]. While confirming that sporadic cases with RAS mutated JMML show long-term survival without treatment, data from the EWOG-MDS did not support a correlation between specific RAS mutation and less aggressive course of the disease implying that children with RAS-mutated JMML who survived without HSCT had normal HbF and high platelet count [31]. It is advised to use these hematologic parameters to identify those few children with RAS mutations in whom a “watch and wait” strategy can be applied until reliable biological parameters able to predict spontaneous resolution of JMML are identified [2].

Our other two patients had confirmed somatic PTPN11 mutation; germline mutation was established in a baby with Noonan syndrome. Patient 2 had been treated with three cycles of AZA with partial hematological response and progressive splenomegaly. Patient 4 presented with hyperleukocytosis and organomegaly, immediately started on low dose azacitidine with remarkable response after the first cycle. However, before the second cycle of AZA he had progression of leukocytosis up to 142 × 10^9/L requiring additional cytoreduction with 6MP and ARA-C; his clinical condition was otherwise normal with no progression of organomegaly. After 4 cycles of AZA he was successfully transplanted now remaining in a complete remission with complete donor chimerism 5 months following HSCT.

### Table 3. Clinical status and laboratory parameters of patients before cytoreductive Th and at the time of HSCT.

<table>
<thead>
<tr>
<th>Patient</th>
<th>Th before the HSCT</th>
<th>Before cytoreductive Th</th>
<th>At the HSCT (before conditioning)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>WBC, x10^9/L</td>
<td>PLT, x10^9/L</td>
<td>BM blasts, %</td>
</tr>
<tr>
<td>1</td>
<td>ARA-C, 6MP</td>
<td>40.75</td>
<td>55.0</td>
</tr>
<tr>
<td>2</td>
<td>Aza 3 cycles, 6MP</td>
<td>38.5</td>
<td>39.0</td>
</tr>
<tr>
<td>3</td>
<td>ARA-C, 6MP</td>
<td>18.24</td>
<td>63.0</td>
</tr>
<tr>
<td>4</td>
<td>Aza 4 cycles, 6MP</td>
<td>16.2</td>
<td>27.0</td>
</tr>
<tr>
<td>5</td>
<td>Aza 3 cycles, ARA-C</td>
<td>131.9</td>
<td>36.0</td>
</tr>
</tbody>
</table>

Th – therapy; UCM – under the costal margin; USG – ultrasonography; PB – peripheral blood; BM – bone marrow; HSCT, hematopoietic stem cell transplantation; ARA-C – cytarabine, dose 40 mg/m² for 5 days; 6MP – mercaptopurine, dose 50 mg/m²; Aza – azacitidine, dose 75 mg/m² for day 1-7 of a 28 days cycle.
Unlike somatic mutations, patients with germline mutations in PTPN11 gene have been reported to have spontaneous resolution of the disease; the gene have codon substitutions that are largely confined to patients with Noonan syndrome as opposed to the spectrum of somatic lesions that occur de novo in JMML. Our patient with germline PTPN11 mutation has been stable for 11 months now on low dose 6MP. He has been closely followed up with no additional treatment required so far.

Currently, molecular genetics and epigenetic mechanisms are the subject of active research in patients with JMML. Several studies established additional secondary mutations of SETBP1 and JAK3 genes that were observed in high-risk patients and were associated with disease progression and poor clinical outcome [32–34]. Recently, based on gene expression profile of leukemic cells, Bresolin et al. reported nonAML-like and AML-like gene expression profiles among 44 patients with JMML; the AML-like type was associated with dismal prognosis, older age, lower platelet count and high HbF at diagnosis [35]. According to the study, no correlations were found between gene-expression profile and specific genetic aberrations in the Ras pathway.

In 2011, the first large study on methylation in JMML patients was published that analyzed the methylation status at fourteen candidate loci [36]. It described CpG island hypermethylation of promoter regions in 4 of the 14 investigated genes (BMP4, CALCA, CDKN2B, RARB), and stated it as the strongest adverse prognostic factor in JMML and as a predictor of relapse after allogeneic HSCT [36]. The aberrant methylation was clonal and the authors considered it as a probable initiating event. Several studies have evaluated the DNA hypermethylation status at various genes and its association with the clinical risk in patients with JMML [37–39]. Recently, another large study has been conducted by EWOG-MDS that analyzed the methylome of leukemic cells of 148 children with JMML [40]. Widespread DNA hypermethylation in leukemic cells was noted in a group of patients with highest cumulative incidence of relapse following HSCT, which demonstrated that DNA hypermethylation is associated with activated RAS signaling and is a hallmark of aggressive JMML [40]. Based on a methylome analysis, the authors identified three clinically relevant JMML subgroups with distinct molecular genetic patterns: the high methylation subgroup (HM) included patients with somatic PTPN11 mutations and cases with poor clinical outcome; the intermediate methylation group (IM), encompassing patients with monosomy 7 and somatic KRAS mutations; the low methylation subgroup (LM) included patients with CBL syndrome and Noonan syndrome with MPD, and patients with a somatic NRAS mutation.

JMML is a fatal disease if left untreated. To eliminate the pathological clone, allogeneic HSCT with myeloablative conditioning, including three alkylating agents is recommended and so far, it remains the only curative treatment with potential to cure more than 50% of patients [2]. The most serious cause of treatment failure is disease recurrence with cumulative incidence reported by some authors to be as high as 35% [41].

For many decades, cytoreductive therapy with 6MP at a 50 mg/m² dose or low dose i.v. cytarabine in a 40 mg/m² dose for 5 days have been used to control the JMML symptoms before the HSCT [42]. In aggressive cases, high dose fludarabine 30 mg/m² and cytarabine 2 g/m² daily for 5 consecutive days have been adopted by some centers [10]. However, neither intensive nor low dose chemotherapy has been demonstrated to improve the outcome of patients with JMML [22].

With an increasing understanding of changes in molecular and epigenetic mechanisms underlying JMML, new potential drugs have come to the healthcare community’s attention. AZA is an inhibitor of DNA methyltransferase that has been used for the treatment of MDS. There has been an increasing number of case reports in literature on the use of low-dose AZA in JMML children before the HSCT, indicating good clinical response and even a complete clinical, cytogenetic and/or molecular genetic remission in a certain proportion of patients with JMML [43, 44]. A phase 2 multicenter clinical trial of AZA has been recently opened in Europe aiming to prospectively evaluate the rate of clinical remission (complete or partial) after 3 cycles of AZA before the HSCT in pediatric patients with newly diagnosed JMML. To control myeloproliferation before HSCT, our three patients (patient 2, 4 and 5; Table 2) received low-dose AZA at a 75 mg/m² dose on day 1 to 7 of 28 days cycle. Patient 2 and 5 had 3 cycles, patient 4 received 4 cycles. Patient 2 had a progression of splenomegaly while on AZA, and after finishing 3 cycles, he required further treatment with 6MP. He was successfully transplanted, but because of a massive splenomegaly interfering with engraftment, he had undergone splenectomy on day 54+ and now remains disease-free 3 years after HSCT. In contrast, both patients 4 and 5 showed impressive response straight after the first cycle of AZA with regression of leukocytosis, splenomegaly, normalization of PLT and reduction of blasts in PB and BM. At the time of HSCT, both were classified as partial response and were successfully transplanted with no major complications (Table 3).

To date, allogeneic HSCT remains the only curative treatment for JMML. With the advent of novel treatment options, targeting epigenome and hypomethylating agents in JMML are increasingly used as a bridging therapy before the transplant. However, incidence and duration of remission induced by hypomethylating agents before the HSCT and its influence on the overall survival following HSCT remains to be answered in prospective multicenter trials.

Acknowledgements: The authors would like to thank colleagues from the European Working Group of Myelodysplastic Syndromes in Childhood (EWOG-MDS), especially Professor Charlotte Niemeyer for the excellent and fruitful co-operation.
References


